Characterization of serum polyunsaturated fatty acid profile in patients with inflammatory bowel disease.
LC-MS technique
essential fatty acid
inflammatory bowel disease
serum polyunsaturated fatty acid
Journal
Therapeutic advances in chronic disease
ISSN: 2040-6223
Titre abrégé: Ther Adv Chronic Dis
Pays: United States
ID NLM: 101532140
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
09
2022
accepted:
25
01
2023
medline:
4
4
2023
entrez:
3
4
2023
pubmed:
4
4
2023
Statut:
epublish
Résumé
Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the digestive tract. The aetiology and pathogenesis of IBD are complex, which may lead to metabolic disorders. As a kind of metabolite, polyunsaturated fatty acid (PUFA) is closely related to IBD. The aim of this study was to explore the correlation between the serum PUFAs and the pathogenesis of IBD. The study is a hospital-based case-control study. The serum free PUFAs of all participants, including 104 patients with IBD and 101 normal controls, were detected by liquid chromatography-mass spectrometry (LC-MS). Compared with the normal control, the levels of C18:2, α-C18:3 (ALA), ɤ-C18:3, C20:4 (AA), C20:5 (EPA), ω-3 C22:5, ω-6 C22:5 and C22:6 (DHA) PUFAs in patients with Crohn's disease (CD) were obviously decreased. However, in patients with ulcerative colitis (UC), the levels of AA, EPA, ω-3 C22:5, ω-6 C22:5 and DHA were downregulated. The concentrations of seven PUFAs were significantly downregulated in the active CD group. In addition, four PUFAs had comparatively higher levels in the remission UC group. The present study revealed substantial differences in the levels of serum fatty acids between normal controls and patients with IBD. In detail, patients with CD were deficient in PUFAs, including the essential fatty acids. Moreover, as the disease activity aggravated, some PUFAs decreased dramatically.
Sections du résumé
Background
UNASSIGNED
Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the digestive tract. The aetiology and pathogenesis of IBD are complex, which may lead to metabolic disorders. As a kind of metabolite, polyunsaturated fatty acid (PUFA) is closely related to IBD.
Objectives
UNASSIGNED
The aim of this study was to explore the correlation between the serum PUFAs and the pathogenesis of IBD.
Design
UNASSIGNED
The study is a hospital-based case-control study.
Methods
UNASSIGNED
The serum free PUFAs of all participants, including 104 patients with IBD and 101 normal controls, were detected by liquid chromatography-mass spectrometry (LC-MS).
Results
UNASSIGNED
Compared with the normal control, the levels of C18:2, α-C18:3 (ALA), ɤ-C18:3, C20:4 (AA), C20:5 (EPA), ω-3 C22:5, ω-6 C22:5 and C22:6 (DHA) PUFAs in patients with Crohn's disease (CD) were obviously decreased. However, in patients with ulcerative colitis (UC), the levels of AA, EPA, ω-3 C22:5, ω-6 C22:5 and DHA were downregulated. The concentrations of seven PUFAs were significantly downregulated in the active CD group. In addition, four PUFAs had comparatively higher levels in the remission UC group.
Conclusion
UNASSIGNED
The present study revealed substantial differences in the levels of serum fatty acids between normal controls and patients with IBD. In detail, patients with CD were deficient in PUFAs, including the essential fatty acids. Moreover, as the disease activity aggravated, some PUFAs decreased dramatically.
Identifiants
pubmed: 37008284
doi: 10.1177/20406223231156826
pii: 10.1177_20406223231156826
pmc: PMC10052691
doi:
Types de publication
Journal Article
Langues
eng
Pagination
20406223231156826Informations de copyright
© The Author(s), 2023.
Déclaration de conflit d'intérêts
The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.
Références
Nutrients. 2020 Sep 10;12(9):
pubmed: 32927614
Clin Nutr. 2017 Jun;36(3):788-792
pubmed: 27289162
J Nutr Metab. 2012;2012:539426
pubmed: 22570770
Scand J Clin Lab Invest. 2011 Feb;71(1):68-73
pubmed: 21142420
Eur J Gastroenterol Hepatol. 2021 Nov 1;33(11):1367-1375
pubmed: 33470696
J Dig Dis. 2019 Oct;20(10):539-546
pubmed: 31347264
J Crohns Colitis. 2020 Nov 7;14(11):1581-1599
pubmed: 32365195
Arch Med Sci. 2022 Jun 03;18(4):1103-1107
pubmed: 35832700
J Nutr. 2019 Jan 1;149(1):57-67
pubmed: 30535058
Gastroenterology. 2011 May;140(6):1785-94
pubmed: 21530745
Inflamm Bowel Dis. 2020 Jan 1;26(1):1-10
pubmed: 31112238
J Dig Dis. 2021 Jun;22(6):298-317
pubmed: 33905603
Nutrients. 2019 May 14;11(5):
pubmed: 31091649
Gastroenterology. 2004 May;126(6):1504-17
pubmed: 15168363
Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):3963-3968
pubmed: 28356517
Dig Liver Dis. 2021 Jul;53(7):809-816
pubmed: 33551353
Sci Rep. 2019 Feb 27;9(1):2882
pubmed: 30814550
Biochim Biophys Acta. 2011 Nov;1811(11):724-36
pubmed: 21689782
World J Gastroenterol. 2014 Oct 7;20(37):13219-33
pubmed: 25309059
Biochem Soc Trans. 2005 Apr;33(Pt 2):423-7
pubmed: 15787620
J Nutr Biochem. 2010 Sep;21(9):781-92
pubmed: 20382009
Nutrients. 2017 Mar 25;9(4):
pubmed: 28346333
Aliment Pharmacol Ther. 2007 Feb 1;25(3):247-55
pubmed: 17217454
PLoS One. 2016 May 26;11(5):e0156387
pubmed: 27227540
Gut. 2014 May;63(5):776-84
pubmed: 23828881
Eur J Gastroenterol Hepatol. 2010 May;22(5):602-6
pubmed: 20216220
Clin Rev Allergy Immunol. 2020 Feb;58(1):82-91
pubmed: 31267470
Nat Commun. 2019 Sep 5;10(1):4007
pubmed: 31488836
Int J Mol Sci. 2017 Dec 07;18(12):
pubmed: 29215589
Am J Clin Nutr. 2008 Jul;88(1):203-9
pubmed: 18614742
Physiol Rev. 2020 Jan 1;100(1):171-210
pubmed: 31487233
J Cancer Res Ther. 2020 Oct-Dec;16(6):1382-1386
pubmed: 33342801
Int J Surg. 2020 Jul;79:294-299
pubmed: 32505647
Pharmacol Ther. 2014 Mar;141(3):272-82
pubmed: 24201219
Eur J Pharmacol. 2011 Sep;668 Suppl 1:S50-8
pubmed: 21816146
Front Med (Lausanne). 2021 Jul 21;8:655404
pubmed: 34368180
J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Aug 1;932:123-33
pubmed: 23831705
Anal Bioanal Chem. 2014 May;406(12):2827-39
pubmed: 24618987
Nat Commun. 2020 Apr 14;11(1):1775
pubmed: 32286299
Gut. 2022 Nov;71(11):2233-2252
pubmed: 35017199
Gastroenterol Hepatol Bed Bench. 2017 Summer;10(3):155-167
pubmed: 29118930
Gastroenterology. 2017 Feb;152(2):313-321.e2
pubmed: 27793607
Am J Gastroenterol. 2010 Aug;105(8):1893-900
pubmed: 20145606
World J Gastroenterol. 2006 Aug 14;12(30):4807-12
pubmed: 16937461
Nutrients. 2021 Jul 06;13(7):
pubmed: 34371835
Inflamm Bowel Dis. 2018 Apr 23;24(5):966-976
pubmed: 29688466
Inflamm Bowel Dis. 2006 Jan;12 Suppl 1:S3-9
pubmed: 16378007
Prostaglandins Leukot Essent Fatty Acids. 2018 May;132:41-48
pubmed: 29610056
J Clin Med. 2021 Feb 06;10(4):
pubmed: 33562024
Nat Rev Gastroenterol Hepatol. 2022 Dec;19(12):753-767
pubmed: 35906289
Am J Clin Nutr. 2021 Apr 6;113(4):832-844
pubmed: 33677550
Trends Neurosci. 1991 Aug;14(8):371-6
pubmed: 1721745
Am J Hematol. 2008 Jun;83(6):437-45
pubmed: 18429055
Clin Sci (Lond). 1987 Oct;73(4):361-4
pubmed: 3665357